AnaptysBio enters the final days of Q3 with a crowded short book, a string of analyst target cuts, and a dense calendar of binary events starting in October.
Short positioning has barely budged since the note published a week ago. Short interest remains near 19.7% of the free float, up roughly 1.3% over the past month and 0.6% on the week. The grind higher is slow but persistent. FINRA's official settlement data through mid-September puts days-to-cover at 10.25, meaning an unwind would take more than two weeks of average volume. That is a genuine structural overhang. And yet the borrow market is not under pressure. Availability is generous at 367%, meaning roughly three-and-a-half shares remain available to borrow for every one already shorted. The cost to borrow has edged up 25% on the week to 0.55%, but that remains historically cheap. The ORTEX short score is steady at 69, a level it has held all month. The positioning looks entrenched rather than aggressive: bears are not paying a premium to stay short.
Options have shifted since last week's note described them as unusually bullish. The put/call ratio has eased back to 1.15, now sitting about 0.9 standard deviations below its 20-day average of 1.35. That means options hedging activity has actually softened relative to recent norms, a mild tilt toward calls after a period when puts dominated from mid-September through last week. The 52-week range on the PCR is extreme, a high of 20.8 and a low of zero, which makes any single-day reading noisy, but the direction of travel this week is less defensive than it was.
The analyst community has been trimming targets without abandoning bullish ratings. JP Morgan cut its price target to $60 from $70 today, while maintaining its Overweight rating. Leerink Partners moved from $90 to $81 last week, also keeping Outperform. HC Wainwright held at $95 with a Buy. The consensus mean price target is $87.25 against a current price of $50.37. That implied return of roughly 73% keeps the Street constructive in aggregate, though the direction of target revisions this month has been uniformly downward. The EPS surprise factor score ranks in the 100th percentile, and EPS momentum over both 30 and 90 days ranks in the top 3% of the universe, a sharp contrast with a forward earnings yield multiple (P/E near 9x) that looks reasonable for a royalty-driven biotech. The stock has fallen 10.5% over the past month and 6.6% this week alone, trading down to levels not far above JP Morgan's freshly lowered target.
The ownership picture adds texture. EcoR1 Capital holds 26.4% of shares, an unusually concentrated anchor. BlackRock added roughly 163,000 shares through August, and State Street added 294,000. Sirenia Capital, however, trimmed its position by 428,000 shares in Q2, dropping to just below the 5% threshold. The activist register carries no 13D filings, meaning no holder has declared an intent to push for change, though the caveat applies: stakes are as-last-disclosed around the 5% level and a holder exiting below that threshold need not file again.
The next print lands November 4, thirty-five days away. Before then, October carries the load: an AZUR-1 trial readout expected around October 25, and a post-trial argument in the GSK royalty dispute on October 20, with judgment expected in Q4 or early Q1. Bears point to a pipeline still concentrated in Phase 2 assets and a diluted share count of 37.3 million fully diluted shares. Bulls anchor to Jemperli's annualised royalty run-rate and patent life extending through 2035 to 2037 depending on region. What to watch is whether the October legal and clinical events shift the balance: short interest has shown no urgency to cover, but the days-to-cover clock and the upcoming binary readouts mean that window is compressing fast.
See the live data behind this article on ORTEX.
Open ANAB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
